VivoSeq
Other

Tenecteplase

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Tenecteplase is an early-stage landscape with 0 programs across 1 company. The most active players are Roche.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting1 · 14%
Withdrawn1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Recruiting·XXuanwu Hospital, Beijing·Phase 3·NCT07253181·572 enrolled
Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
Not yet recruiting·TThe First Affiliated Hospital of University of Science and Technology of China·Phase 3·NCT07168278·794 enrolled
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Completed·Roche logoRoche·Phase 3·NCT00395876·100 enrolled
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Completed·Roche logoRoche·Phase 3·NCT00396318·251 enrolled
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
Completed·SSupergene, LLC·Phase 3·NCT02301910·382 enrolled
Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
Completed·—·N/A·NCT06018181·2,408 enrolled
Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion
Withdrawn·UUniversity Hospital Center of Martinique·Phase 2·NCT02338466

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)